Cat. No.: DIA-0243225
Product Information | |
---|---|
CAS No. | 250694-07-6 |
Formula | C22H45N3O3 |
Molecular Weight | 399.61 |
SMILES | O=C(N[C@H](CC([O-])=O)C[N+](C)(C)C)NCCCCCCCCCCCCCC |
Target | Endogenous Metabolite |
Product Description | Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD). |
Format & Storage | |
---|---|
Format | Solid |
Color | White to off-white |
Purity | ≥98.0% |
Shipping | Room temperature in the continental U.S. Other areas may vary. |
Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 6 months; -20°C, 1 month |
Solubility Overview | Ethanol : 100 mg/mL DMSO : 19 mg/mL H2O : 10 mg/mL |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.